Tej K. Mattoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tej K. Mattoo has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Gaurav Kapur
Children’s Hospital of Michigan
5 shared publicationsRanjiv Mathews
Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA
4 shared publicationsRudolph P. Valentini
Division of Nephrology and Hypertension, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan
4 shared publicationsAmrish Jain
Children’s Hospital of Michigan
3 shared publications- Indra Rani Gupta
Department of Pediatrics, Division of Pediatric Nephrology, Montreal Children's Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
3 shared publications - Marva Moxey-Mims
Division of Pediatric Nephrology, Department of Pediatrics, Children's National Hospital, The George Washington University School of Medicine, Washington, DC
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Saudi Journal of Kidney Diseases and Transplantation
- Vol. 37 (3) , 136-143
Chronic dehydration in older adults: An underestimated health hazard
In contrast to acute dehydration, which is usually recognized through identifiable risk factors, clinical signs, and laboratory abnormalities, chronic dehydration develops insidiously and frequently goes unrecognized. This is particularly true in older adults, among whom many of its nonspecific manifestations, such as weakness, constipation, headache, dizziness, gait instability, and confusion, are often mistakenly attributed to normal aging. This population is especially vulnerable to chronic dehydration because of age-related normal physiological changes, compounded by physical, cognitive, psychological, climate, and other environmental influences. Inadequate hydration is associated with impairments in physical, cognitive, and emotional functioning, reduced alertness, and diminished exercise tolerance. It may also alter drug pharmacokinetics and pharmacodynamics, increasing the risk of medication-related adverse events. Emerging evidence suggests that chronic dehydration contributes to neurocognitive decline and the progression of some chronic diseases, while increasing susceptibility to acute fluid deficits associated with substantial morbidity and mortality. Because its presentation is often subtle and nonspecific, recognizing chronic dehydration in older adults, including those who are otherwise healthy, requires a high index of suspicion. Greater awareness is essential for prevention, early detection, and management of chronic dehydration in this vulnerable population.
- 1 July 2026
- Published by Wolters Kluwer Health in Saudi Journal of Kidney Diseases and Transplantation
- Vol. 37 (3) , 136-143
Open AccessChronic dehydration in older adults: An underestimated health hazard
In contrast to acute dehydration, which is usually recognized through identifiable risk factors, clinical signs, and laboratory abnormalities, chronic dehydration develops insidiously and frequently goes unrecognized. This is particularly true in older adults, among whom many of its nonspecific manifestations, such as weakness, constipation, headache, dizziness, gait instability, and confusion, are often mistakenly attributed to normal aging. This population is especially vulnerable to chronic dehydration because of age-related normal physiological changes, compounded by physical, cognitive, psychological, climate, and other environmental influences. Inadequate hydration is associated with impairments in physical, cognitive, and emotional functioning, reduced alertness, and diminished exercise tolerance. It may also alter drug pharmacokinetics and pharmacodynamics, increasing the risk of medication-related adverse events. Emerging evidence suggests that chronic dehydration contributes to neurocognitive decline and the progression of some chronic diseases, while increasing susceptibility to acute fluid deficits associated with substantial morbidity and mortality. Because its presentation is often subtle and nonspecific, recognizing chronic dehydration in older adults, including those who are otherwise healthy, requires a high index of suspicion. Greater awareness is essential for prevention, early detection, and management of chronic dehydration in this vulnerable population.
- 27 April 2026
- Published by Springer Nature in Pediatric Nephrology
Reassessing the role of kidney biopsy in early idiopathic steroid-resistant nephrotic syndrome among children and young adults
About 90% of cases with idiopathic nephrotic syndrome (NS) respond to corticosteroids. The remaining 10%, classified as steroid-resistant nephrotic syndrome (SRNS), typically undergo a kidney biopsy before receiving additional immunosuppression. This study examined the extent to which kidney biopsy findings influenced management in children and young adults with newly diagnosed idiopathic SRNS. We conducted a retrospective chart review of patients aged 1-21 years and diagnosed with SRNS at the Detroit Medical Center from January 2000 to December 2024. Exclusion criteria were patients with syndromic diagnoses and presentation with gross hematuria, hypertension, or identifiable systemic disease. The study included 55 patients, 46 underwent kidney biopsy after the diagnosis of SRNS (mean age 10.9 ± 4.6 years), and 9 had elective biopsies based on age before being diagnosed with SRNS (mean age 16 ± 1.7 years). Biopsy diagnoses included focal segmental glomerulosclerosis (72%), minimal change disease (24%), and membranous nephropathy (4%). Sixty-five percent of cases had mild to moderate interstitial fibrosis/tubular atrophy. Most patients (84%) were admitted overnight, 71% had flank or back pain, and 15% had a hematoma. Post-biopsy, 96% of patients received calcineurin inhibitors (CNIs): cyclosporine (n = 38) or tacrolimus (n = 15). At one year, 96% remained on CNIs. Kidney biopsy did not significantly alter immunosuppressive management in newly diagnosed patients with SRNS at our center. Larger multicenter studies are needed to confirm these findings and evaluate whether more selective biopsy criteria could spare patients from a potentially avoidable invasive procedure, improve clinical management, and reduce healthcare costs.
- 27 April 2026
- Published by Springer Nature in Pediatric Nephrology
Reassessing the role of kidney biopsy in early idiopathic steroid-resistant nephrotic syndrome among children and young adults
About 90% of cases with idiopathic nephrotic syndrome (NS) respond to corticosteroids. The remaining 10%, classified as steroid-resistant nephrotic syndrome (SRNS), typically undergo a kidney biopsy before receiving additional immunosuppression. This study examined the extent to which kidney biopsy findings influenced management in children and young adults with newly diagnosed idiopathic SRNS. We conducted a retrospective chart review of patients aged 1-21 years and diagnosed with SRNS at the Detroit Medical Center from January 2000 to December 2024. Exclusion criteria were patients with syndromic diagnoses and presentation with gross hematuria, hypertension, or identifiable systemic disease. The study included 55 patients, 46 underwent kidney biopsy after the diagnosis of SRNS (mean age 10.9 ± 4.6 years), and 9 had elective biopsies based on age before being diagnosed with SRNS (mean age 16 ± 1.7 years). Biopsy diagnoses included focal segmental glomerulosclerosis (72%), minimal change disease (24%), and membranous nephropathy (4%). Sixty-five percent of cases had mild to moderate interstitial fibrosis/tubular atrophy. Most patients (84%) were admitted overnight, 71% had flank or back pain, and 15% had a hematoma. Post-biopsy, 96% of patients received calcineurin inhibitors (CNIs): cyclosporine (n = 38) or tacrolimus (n = 15). At one year, 96% remained on CNIs. Kidney biopsy did not significantly alter immunosuppressive management in newly diagnosed patients with SRNS at our center. Larger multicenter studies are needed to confirm these findings and evaluate whether more selective biopsy criteria could spare patients from a potentially avoidable invasive procedure, improve clinical management, and reduce healthcare costs.
- 10 October 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1-18
Primary vesicoureteral reflux
Primary vesicoureteral reflux (VUR) is one of the most common urological abnormalities in infants and children. The association of VUR, urinary tract infection (UTI) and renal parenchymal damage is well established. The most serious complications of VUR-associated reflux nephropathy are hypertension and proteinuria with chronic kidney disease. Over the past two decades, our understanding of the natural history of VUR has improved, which has helped to identify patients at increased risk of both VUR and VUR-associated renal injury. The main goals in the treatment of paediatric patients with VUR are the prevention of recurrent UTIs and minimizing the risk of renal scarring and long-term renal impairment. Currently, there are four options for managing primary VUR in infants and children: surveillance or intermittent treatment of UTIs with management of bladder and bowel dysfunction; continuous antibiotic prophylaxis; endoscopic subureteral injection of tissue-augmenting substances; and ureteral reimplantation via open, laparoscopic or robotic-assisted surgery. Current debates regarding key aspects of management include when to perform diagnostic imaging and how to best identify the paediatric patients that will benefit from continuous antibiotic prophylaxis or surgical intervention, including endoscopic injection therapy and minimally invasive ureteral reimplantation. Evolving technologies, such as artificial intelligence, have the potential to assist clinicians in the decision-making process and in the individualization of diagnostic imaging and treatment of infants and children with VUR in the future.
- 10 October 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1-18
Primary vesicoureteral reflux
Primary vesicoureteral reflux (VUR) is one of the most common urological abnormalities in infants and children. The association of VUR, urinary tract infection (UTI) and renal parenchymal damage is well established. The most serious complications of VUR-associated reflux nephropathy are hypertension and proteinuria with chronic kidney disease. Over the past two decades, our understanding of the natural history of VUR has improved, which has helped to identify patients at increased risk of both VUR and VUR-associated renal injury. The main goals in the treatment of paediatric patients with VUR are the prevention of recurrent UTIs and minimizing the risk of renal scarring and long-term renal impairment. Currently, there are four options for managing primary VUR in infants and children: surveillance or intermittent treatment of UTIs with management of bladder and bowel dysfunction; continuous antibiotic prophylaxis; endoscopic subureteral injection of tissue-augmenting substances; and ureteral reimplantation via open, laparoscopic or robotic-assisted surgery. Current debates regarding key aspects of management include when to perform diagnostic imaging and how to best identify the paediatric patients that will benefit from continuous antibiotic prophylaxis or surgical intervention, including endoscopic injection therapy and minimally invasive ureteral reimplantation. Evolving technologies, such as artificial intelligence, have the potential to assist clinicians in the decision-making process and in the individualization of diagnostic imaging and treatment of infants and children with VUR in the future.
- 14 March 2024
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (10) , 2833-2844
Biomarkers for urinary tract infection: present and future perspectives
A prompt diagnosis of urinary tract infection (UTI) is necessary to minimize its symptoms and limit sequelae. The current UTI screening by urine test strip analysis and microscopic examination has suboptimal diagnostic accuracy. A definitive diagnosis of UTI by urine culture takes two to three days for the results. These limitations necessitate a need for better biomarkers for the diagnosis and subsequent management of UTI in children. Here, we review the value of currently available UTI biomarkers and highlight the potential of emerging biomarkers that can facilitate a more rapid and accurate UTI diagnosis. Of the newer UTI biomarkers, the most promising are blood procalcitonin (PCT) and urinary neutrophil gelatinase-associated lipocalin (NGAL). PCT can provide diagnostic benefits and should be considered in patients who have a blood test for other reasons. NGAL, which is on the threshold of clinical care, needs more research to address its scope and utilization, including point-of-care application. Employment of these and other biomarkers may ultimately improve UTI diagnosis, guide UTI therapy, reduce antibiotic use, and mitigate UTI complications. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 14 March 2024
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (10) , 2833-2844
Biomarkers for urinary tract infection: present and future perspectives
A prompt diagnosis of urinary tract infection (UTI) is necessary to minimize its symptoms and limit sequelae. The current UTI screening by urine test strip analysis and microscopic examination has suboptimal diagnostic accuracy. A definitive diagnosis of UTI by urine culture takes two to three days for the results. These limitations necessitate a need for better biomarkers for the diagnosis and subsequent management of UTI in children. Here, we review the value of currently available UTI biomarkers and highlight the potential of emerging biomarkers that can facilitate a more rapid and accurate UTI diagnosis. Of the newer UTI biomarkers, the most promising are blood procalcitonin (PCT) and urinary neutrophil gelatinase-associated lipocalin (NGAL). PCT can provide diagnostic benefits and should be considered in patients who have a blood test for other reasons. NGAL, which is on the threshold of clinical care, needs more research to address its scope and utilization, including point-of-care application. Employment of these and other biomarkers may ultimately improve UTI diagnosis, guide UTI therapy, reduce antibiotic use, and mitigate UTI complications. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Open Access
- 31 May 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 340-348
Body water percentage from childhood to old age
Background: Total body water (TBW) increases with growth, but the body water percentage (TBW%) decreases with aging. The objective of our study was to delineate TBW% in males and females by bioelectrical impedance analysis (BIA) from early childhood to old age. Methods: We enrolled 545 participants aged 3 to 98 years (258 male, 287 female). Among the participants, 256 had a normal weight and 289 were overweight. The TBW was measured by BIA, and TBW% was derived by dividing the TBW (L) value by body weight (kg). For analysis, we divided participants into the four age groups of 3–10, 11–20, 21–60, and ≥61 years.Results: In normal-weight subjects, the TBW% was similar at 62% between males and females in the 3–10-year group. It remained unchanged in males until and through adult life, then decreased to 57% in the ≥61-year group. In normal-weight female subjects, the TBW% decreased to 55% in the 11–20-year group, remained relatively unaltered in the 21–60-year group, then decreased to 50% in the ≥61-year group. In overweight subjects, the TBW% values in males, as well as females, were significantly lower as compared to those with normal weight. Conclusion: Our study showed that the TBW% in normal-weight males changes very little from early childhood to adult life compared to that of females, who showed a decrease in TBW% during the pubertal years. In normal-weight subjects of both sexes, the TBW% decreased after the age of 60 years. Overweight subjects had significantly lower TBW% as compared to those with normal weight.
- 31 May 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 340-348
Open AccessBody water percentage from childhood to old age
Background: Total body water (TBW) increases with growth, but the body water percentage (TBW%) decreases with aging. The objective of our study was to delineate TBW% in males and females by bioelectrical impedance analysis (BIA) from early childhood to old age. Methods: We enrolled 545 participants aged 3 to 98 years (258 male, 287 female). Among the participants, 256 had a normal weight and 289 were overweight. The TBW was measured by BIA, and TBW% was derived by dividing the TBW (L) value by body weight (kg). For analysis, we divided participants into the four age groups of 3–10, 11–20, 21–60, and ≥61 years.Results: In normal-weight subjects, the TBW% was similar at 62% between males and females in the 3–10-year group. It remained unchanged in males until and through adult life, then decreased to 57% in the ≥61-year group. In normal-weight female subjects, the TBW% decreased to 55% in the 11–20-year group, remained relatively unaltered in the 21–60-year group, then decreased to 50% in the ≥61-year group. In overweight subjects, the TBW% values in males, as well as females, were significantly lower as compared to those with normal weight. Conclusion: Our study showed that the TBW% in normal-weight males changes very little from early childhood to adult life compared to that of females, who showed a decrease in TBW% during the pubertal years. In normal-weight subjects of both sexes, the TBW% decreased after the age of 60 years. Overweight subjects had significantly lower TBW% as compared to those with normal weight.
- 28 May 2023
- Published by Springer Nature
- p. 125-142
Chronic Kidney Disease
- 26 November 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 53, 53-59
A new prediction model for total body water estimation by BIA in children with normal and excessive weight
- 26 November 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 53, 53-59
A new prediction model for total body water estimation by BIA in children with normal and excessive weight
- Open Access
- 2 November 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 1043285
Duration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response
Background: The duration of initial corticosteroid therapy in newly diagnosed Idiopathic nephrotic syndrome (INS) is about 3 months. Our study was designed to test the feasibility of a shorter duration of corticosteroid therapy in newly diagnosed INS who show a quicker response.Methods: Patients who responded within 10 days (Group A) received 8 weeks of corticosteroid therapy as compared to 12–14 weeks of standard therapy in those who responded between >10 days to 28 days (Group B), and follow up for 52 weeks. The primary endpoint is time to first relapse after treatment completion. (NCT03878914, March 18, 2019)Results: A total of 33 children with INS were enrolled and the follow-up data were analyzed. The clinical and laboratory characteristics of patients in both groups were similar. No significant difference was found in time to first relapse [65(14.5, 159) days for Group A vs. 28(17, 61.5) days for Group B, P = 0.371], the incidence of frequently relapsing nephrotic syndrome [6/18 (33.3%) vs. 5/10(50%), P = 0.644] or requirement for alternative immunosuppressant [4/18 (22.2%) vs. 1/10 (10%), P = 0.769]. Group A received similar corticosteroid dose compare with Group B (3511 ± 2421 mg/m2 vs. 4117 ± 2556 mg/m2, P = 0.524). Frequency and severity of corticosteroid-related complications was similar in both groups.Conclusions: The time to first relapse and the number of relapses per patient were comparable between the two groups. However, more patients in Group A relapsed and the mean total dose of prednisolone for the study period was very similar between the two groups.
- 2 November 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 1043285
Open AccessDuration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response
Background: The duration of initial corticosteroid therapy in newly diagnosed Idiopathic nephrotic syndrome (INS) is about 3 months. Our study was designed to test the feasibility of a shorter duration of corticosteroid therapy in newly diagnosed INS who show a quicker response.Methods: Patients who responded within 10 days (Group A) received 8 weeks of corticosteroid therapy as compared to 12–14 weeks of standard therapy in those who responded between >10 days to 28 days (Group B), and follow up for 52 weeks. The primary endpoint is time to first relapse after treatment completion. (NCT03878914, March 18, 2019)Results: A total of 33 children with INS were enrolled and the follow-up data were analyzed. The clinical and laboratory characteristics of patients in both groups were similar. No significant difference was found in time to first relapse [65(14.5, 159) days for Group A vs. 28(17, 61.5) days for Group B, P = 0.371], the incidence of frequently relapsing nephrotic syndrome [6/18 (33.3%) vs. 5/10(50%), P = 0.644] or requirement for alternative immunosuppressant [4/18 (22.2%) vs. 1/10 (10%), P = 0.769]. Group A received similar corticosteroid dose compare with Group B (3511 ± 2421 mg/m2 vs. 4117 ± 2556 mg/m2, P = 0.524). Frequency and severity of corticosteroid-related complications was similar in both groups.Conclusions: The time to first relapse and the number of relapses per patient were comparable between the two groups. However, more patients in Group A relapsed and the mean total dose of prednisolone for the study period was very similar between the two groups.
- 29 October 2022
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 69 (6) , XV-XVII
A Gamut of Kidney Diseases in Children
- 29 October 2022
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 69 (6) , XV-XVII
A Gamut of Kidney Diseases in Children